Harpoon Therapeutics (Harpoon Therapeutics) Cash-to-Debt : 2.18 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Harpoon Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2023 was 2.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Harpoon Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Harpoon Therapeutics's Cash-to-Debt or its related term are showing as below:

HARP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 9.33 Max: No Debt
Current: 2.18

During the past 7 years, Harpoon Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.43. And the median was 9.33.

HARP's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.46 vs HARP: 2.18

Harpoon Therapeutics Cash-to-Debt Historical Data

The historical data trend for Harpoon Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Harpoon Therapeutics Cash-to-Debt Chart

Harpoon Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

9.91

9.33

11.09

3.32

Harpoon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															6.02	3.32	3.93	3.00	2.18

Competitive Comparison of Harpoon Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Harpoon Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harpoon Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's Cash-to-Debt falls into.

Harpoon Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Harpoon Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	53.112	/	(2.423	+	13.583)
	=	3.32

Harpoon Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	31.608	/	(2.974	+	11.53)
	=	2.18

Harpoon Therapeutics (NAS:HARP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Harpoon Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

5HTA:Germany

Address

131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Executives

Vijay K Lathi	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker	officer: Chief Medical Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza	officer: Principal Fin. & Acctng Ofc.	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail	director	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez	officer: Chief Financial Officer	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick	director	C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt	director, 10 percent owner	C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170